Clinical Trial

CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

Study acronym: NANOCLAMP-AF
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-28; most recent amendment 2026-01-09.
Status change: Not Yet Recruiting → Recruiting 2025-12-11
Trial Details
NCT Number NCT06959121
Lead Sponsor Pulse Biosciences, Inc.
Collaborators: Avania
Conditions Atrial Fibrillation, Maze Procedure, AF, Ablation
Enrollment 135 participants
Start Date 2025-10-23
Primary Completion 2027-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-12